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Purpose: Tumor necrosis factor-α (TNF-α), an important proinflammatory cytokine, exerts a variety of physiologic and
pathogenic effects that lead to tissue destruction. Recent laboratory evidence indicates that TNF-α have either protective
or adverse effects on primary open angle glaucoma (POAG). Inheritance of the TNF-α (−863) C allele has been associated
with an elevated risk of Alzheimer disease. The neuronal injuries associated with Alzheimer disease have several
similarities with the optic nerve changes often seen with POAG. In this study we investigated the possible association
between the TNF-α (−863) polymorphism and the development of POAG.
Methods: A total of 234 patients with POAG were recruited and compared with 230 healthy controls in a Chinese
population. Sequence-specific primers with 3′ end mismatches were used to identify the presence of specific allelic variants
by polymerase chain reaction (PCR) amplification. Patients and controls were genotyped for the A/C polymorphism at
position −863 of the TNF-α gene promoter region.
Results: The frequency of the TNF-α (−863)A allele (22% versus 30%, respectively; p=0.007) and the carriers of the
TNF-α (−863)A allele (37% versus48%; p=0.017, OR 0.63, 95% CI 0.44–0.92) were lower in POAG patients compared
with those in controls. There is a reduced risk of POAG associated with homozygosity for the TNF-α (−863)A allele (AA
genotype) compared with that in the control population (AA genotype; 7% versus 11%, respectively, p=0.037; OR 0.5,
95% CI 0.26–0.98).
Conclusions: The TNF-α (−863)A allele polymorphism may be a protective factor in the development of POAG.
Glaucoma  is  a  progressive  optic  neuropathy
characterized  by  degeneration  of  retinal  ganglion  cells,
cupping of the optic nerve heads and visual field defects often
related to elevated intraocular pressure. Glaucoma affects 70
million people worldwide, and constitutes the second largest
cause of bilateral blindness in the world [1]. Primary open
angle glaucoma (POAG) is a multifactorial neurodegenerative
disease. Both genetic and environmental factors are thought
to contribute to the pathophysiology of the disease.
Glaucoma is a complex clinical trait and its inheritance
has been shown to follow both Mendelian and non-Mendelian
models [2]. At least eight loci of genes have been found to be
associated with POAG, such as myocilin (MYOC), optineurin
(OPTN) and WD repeat domain 36 (WDR36) [3-6]. Mutation
in  the  optineurin  gene  was  initially  reported  in  16.7%  of
families with hereditary POAG, with most of them having
normal tension glaucoma [4]. Cytochrome P450, family 1,
subfamily B, polypeptide 1(CYP1B1) and latent-transforming
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growth factor beta-binding protein 2 (LTBP2) mutations are
more  frequent  in  congenital  and  developmental  glaucoma
[7-9]. Other genetic factors, e.g., optic atrophy 1 (OPA1),
apolipoprotein E, E-cadherin, neurotrophin-4 (NTF-4) and
opticin (OPTC), have been reported to elevate the risk of
retinal degeneration, a characteristic of glaucoma [10-14].
However,  these  genes  can  not  account  for  the  overall
inheritance of susceptibility to POAG pathogenesis. Other
associations involved in the development of POAG should
also  be  investigated.  Genetic  association  studies  aimed  at
defining  susceptibility  to  POAG  may  provide  important
insights into the pathogenesis of POAG.
There  is  evidence  to  support  the  hypothesis  that  the
immune  system  plays  a  potential  pathogenic  role  in
glaucomatous optic nerve degeneration [15,16]. Balancing the
benefit of protective immunity and the risk of inducing an
autoimmune  neurodegenerative  disease  is  critical,  as  the
effect  of  such  immune  regulation  may  be  either
neuroprotective  or  neurodestructive  [17].  T-cell  mediated
immune  response  may  initially  be  beneficial  in  limiting
neurodegeneration. However, a failure to properly control
aberrant, stress-induced immune response likely converts the
protective  immunity  to  an  autoimmune  neurodegenerative
process  that  can  facilitate  the  progression  of
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779neurodegeneration  in  glaucoma  patients  [17,18].  For
example, increased numbers of auto-antibodies were found in
the serum of glaucoma patients, and such auto-antibodies
include those with specificities to heat shock proteins such as
heat shock protein 60 (HSP60) and HSP27, alpha crystallins
and HSP70 [19,20]. Tumor necrosis factor-α (TNF-α) is a
contributing  factor  in  the  neurodegeneration  in  glaucoma
[21-24].The  association  between  the  degree  of  immune
responses and the development of glaucomatous optic nerve
degeneration may be fluid, and in certain cases may result in
retinal  ganglion  cell  death  through  an  aberrant  immune
signaling process.
A C/A polymorphism at position −863 of the TNF-α
promoter  region  has  been  reported  to  be  associated  with
Alzheimer disease [25,26]. There is evidence that the TNF-α
protein may act to promote the development of β-amyloid
deposits [27]. Similar evidence also indicates that there is β-
amyloid  build-up  in  retinal  ganglion  cells  in  rats  with
experimental  glaucoma  [28,29].  Tamura  et  al.  [30]  have
shown a high frequency of POAG in patients with Alzheimer
disease. In this regard, glaucoma may be viewed as a chronic
neurodegenerative disease similar to Alzheimer disease, and
a slow build up of β-amyloid in ganglion cells may eventually
trigger cell death and optic nerve axon loss.
Recent studies have shown that ischemic or pressure-
loaded  glial  cells  produce  TNF-α,  which  results  in
oligodendrocytes  death  and  the  subsequent  apoptosis  of
retinal ganglion cells [31]. Tezel et al. [21] found that TNF-
α or TNF-α receptor-1 (TNF-R1) are raised in the retina of
glaucomatous  eyes  compared  with  levels  in  normal  eyes,
suggesting that cell death mediated by TNF-α is a contributing
factor in neurodegeneration in glaucoma. Balaiya et al. [32]
found TNF-α levels in aqueous humor were elevated in patient
with  POAG.  Other  evidence  showed  that  anti-  TNF-α
antibodies can prevent death of retinal ganglion cells (RGCs)
by  reducing  ocular  hypertension,  which  indicates  that
reducing the expression of TNF-α would be beneficial in
treating glaucoma [33].
To  date,  several  publications  have  evaluated  the
association  between  TNF-α  promoter  polymorphisms  and
glaucoma  risk  [34-39].  However,  the  results  remain
inconclusive. Inheritance of the TNF-α (−863) C allele has
been associated with an elevated risk of Alzheimer disease. A
C/A  polymorphism  at  position  −863  of  TNF-α  promoter
region  is  considered  to  be  an  important  enhancer  of
transcriptional activation associated with elevated levels of
TNF-α.  Given  the  potential  similarities  in  cellular  events
leading to neurodegeneration between Alzheimer disease and
glaucoma, we hypothesized that TNF-α (−863) polymorphism
may be a genetic factor predisposing affected individuals to
glaucoma due to its effect on TNF-α protein expression. Thus,
we  investigated  the  distribution  of  the  TNF-α  (−863)
polymorphism in patients with POAG and compared them
with that in a healthy control population.
METHODS
Study subjects: Subjects were recruited from the outpatient
clinic  at  the  Department  of  Ophthalmology  of  Taichung
Veterans General Hospital, Taiwan from January 2009 to July
2011. POAG patients were invited to participate in the study
when they came to the clinic for a previously scheduled visit,
and  were  enrolled  after  informed  consent  was  obtained.
Normal control subjects were recruited during their visits to
the outpatient clinic for various other reasons. In total, 234
patients with POAG and 230 normal controls were enrolled
(Table 1). The mean age was 67 years in the POAG group
(range 25–78) and 67 years in the control group (range 44–
79). There was no difference in age between the control and
POAG  groups  (p>0.05).  Patients  were  followed  up  for
between 1 and 10 years (with a mean of 5 years). Twenty-one
of the patients had received trabeculectomy and four of the 21
patients had received trabeculectomy twice from different
sites.  Of  the  POAG  patients,  217  were  prescribed
antiglaucoma  eyedrops.  All  medical  treatment  primarily
included  topical  beta-blockers  and  prostaglandin.  Each
patient used an average of 1.4 types of antiglaucoma drugs.
Seventeen  patients  did  not  need  medication  to  control
intraocular pressure (IOP) after trabeculectomy.
All participants received comprehensive ophthalmologic
examinations, including visual acuity testing with refraction,
corneal thickness, IOP measurement, Humphrey 30–2, slit
lamp  examination,  Stratus  optical  coherence  tomography
(Carl Zeiss Meditec, Inc., Dublin, CA), and dilated slit lamp
stereo biomicroscopy.
Comprehensive ophthalmologic history and longitudinal
follow-up data were also obtained for each individual. The
TABLE 1. BASELINE CHARACTERISTICS OF PATIENTS AND CONTROLS.
 Parameter POAG (n=234) Control (n=230)
Mean age (years) 67 67
Range (years) 25–78 44–79
Male (%) 52 53
Mean IOP (±SD; mmHg) 26±3.5 17±2.1
Mean vertical cup-disc ratio (±SD) 0.84±0.13 0.4±0.10
          IOP: intraocular pressure; SD: standard deviation.
Molecular Vision 2012; 18:779-785 <http://www.molvis.org/molvis/v18/a83> © 2012 Molecular Vision
780definition of POAG included characteristic arcuate, Bjerrum,
Seidel  and/or  paracentral  scotoma  and/or  nasal  step  on
Humphrey 30–2 with reference to Anderson’s criteria for
minimal abnormality in glaucoma [40], and corresponding
cupping of optic nerve heads and/or nerve fiber layer defects
on  stereo  biomicroscopy,  open  drainage  angles  on
gonioscopy,  and  the  absence  of  a  secondary  cause  of
glaucomatous optic neuropathy, such as previous trauma, a
period of steroid administration, or uveitis. The POAG cases
had an elevated IOP of >21 mmHg on diurnal testing. Patients
with  a  history  of  inflammation,  ocular  hypertension,
congenital  glaucoma  or  normal  tension  glaucoma  were
excluded.
Unrelated  control  subjects  were  recruited  from  those
attending  the  clinic  for  senile  cataract,  floaters,  refractive
errors,  or  itchy  eye.  All  normal  control  subjects  had  no
systemic  disease  and  no  family  history  of  glaucoma.
Glaucoma  in  these  patients  was  excluded  using  the  same
diagnostic criteria used for the POAG patients after the same
ophthalmic examination procedure. If there was any doubt
whether  the  subject  had  NTG  or  POAG,  the  subject  was
excluded. The study was performed with the approval of the
Human  Study  Committee  of  Taichung  Veterans  General
Hospital. Written informed consent was obtained from all
study subjects before enrollment.
DNA  preparation  and  genotyping:  Blood  samples  were
collected from each subject (5 ml) and genomic DNA was
isolated using the Quiagen QiaAmp Blood mini kit (Quiagen,
Valencia,  CA).  Polymorphisms  were  determined  using
sequence-specific primers (SSPs). PCR-SSP uses SSPs with
3′ end mismatches and identifies the presence of specific
allelic  variants  through  PCR  amplification.  For  the
polymorphisms in the TNF-α (−863), we used the primer
sequences  and  primer  mixtures  previously  described  by
Fanning et al. [41] and Grutters et al. [42]. The promoter
polymorphism -863(C/A) was identified with the sequence-
specific  forward  primers  5’-CGA  GTA  TGG  GGA  CCC
CCC-3'  and  5’-GAG  TAT  GGG  GAC  CCC  CA-3'  in
combination  with  the  consensus  reverse  primers  5’-CCG
GGA ATT CAC AGA CCC C-3' at a final concentration of
20 ng/μl, with an expected PCR product size of 263 bp.
PCR products were run on ethidium bromide-stained 2%
agarose  gels.  We  sequenced  the  5′  regulatory  region
(containing the promoter) of TNF-α in selected individuals
with each genotype (CC, CA, and AA) to confirm the validity
of PCR assay. Complete matching results in PCR assay and
DNA sequence were obtained. To ensure accuracy, each test
was performed three times for each sample.
Statistical analysis: Genotype and allele frequencies between
the control and POAG groups were compared using the χ2 test,
and Fisher’s exact test was used if any expected frequency
was lower than 5. Age and gender were compared between
the control and POAG groups using the Mann–Whitney U test
and χ2 test, respectively. Odds ratios were computed to assess
the strength of associations between the presence of each
genotype and the clinical diagnosis of POAG. A p-value of
less than 0.05 was considered statistically significant. All
statistical analyses were performed using SPSS 13.0 (SPSS
Inc., Chicago, IL).
RESULTS
TNF-α (−863) A association with reduced risk of POAG: The
distributions  of  TNF-α  (−863)  genotypes  and  alleles  are
shown in Table 1. In POAG patients, the genotype TNF-α
(−863)A/A was less frequent than in controls (7% versus 11%;
p=0.037; Table 2). The frequency of the TNF-α (−863)A allele
was significantly decreased in POAG group (22% versus30%,
p=0.007).  In  comparison  with  controls  there  were
significantly  fewer  carriers  of  the  TNF-α  (−863)  A  allele
among patients with POAG (37% versus 48%; p=0.017), with
an odds ratio of 0.63 (95% CI: 0.44–0.92; Table 2). The
distribution of genotypes in the population of patients and
controls  was  consistent  with  the  Hardy–Weinberg
equilibrium,  with  no  significant  detectable  differences
between expected and observed numbers.
DISCUSSION
In this study, the genotype TNF-α (−863)AA was less frequent
in POAG patients than in controls (7% versus 11%; p=0.037).
The frequency of the TNF-α (−863)A allele was significantly
decreased in POAG group (22% versus30%, p=0.007). There
were significantly fewer carriers (AA or CA) of the TNF-α
(−863) A allele among patients with POAG than control (37%
versus 48%). Our results indicate that TNF-α (−863) A allele
polymorphism may be a protective factor in the development
of POAG. Inheritance of the TNF-α (−863) C allele has been
associated with elevated risk of developing Alzheimer disease
[25,26]. There is evidence that the TNF-α protein may act to
promote the development of β-amyloid deposits in Alzheimer
patients [27], and McKinnon and colleagues [28,29] have
demonstrated evidence of build up of β-amyloid in retinal
ganglion cells in a rat glaucoma model. The death of retinal
ganglion  cells  in  glaucoma  involving  chronic  β-amyloid
neurotoxicity may mimic Alzheimer disease at the molecular
level. These data point to a potential overlap between the
degenerative  pathways  underlying  POAG  and  Alzheimer
disease.
TNF-α,  a  pleoprotic  proinflammatory  cytokine,  is
upregulated in several neurodegenerative disorders including
multiple  sclerosis,  Parkinson  disease,  Alzheimer  disease
[43,44], multiple sclerosis [45], and in optic nerve microglia
and astrocytes in glaucoma patients [46,47]. TNF-α has either
protective or adverse effects on POAG. TNF-α is considered
to  exert  a  neuroprotective  effect,  because  it  activates  the
ubiquitous transcription factor, nuclear factor kappa B (NF-
κB),through binding to the high affinity TNF receptor (TNF-
R2). TNF-α can also serve as a neurodegenerative factor when
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781it binds to the low affinity death receptor TNF-R1 and induces
the mitochondria-mediated apoptotic pathway [48-52]. An
increased expression of TNF-α can shift the balance toward
TNF-R1 signaling, as seen in glaucoma, and thus promote
retinal ganglion cell death. Increased TNF-α levels have been
associated with a poor prognosis after trauma in the brain
[53], whereas a decrease in TNF-α is known to reduce nerve
damage [54].
The TNF gene lies within the human leukocyte antigen
(HLA) class III region, located 250 kb centromeric to the HLA-
B locus and 850 kb telomeric to the class II HLA-DR locus on
chromosome  6p21.3.  Recent  studies  have  reported  new
promoter  polymorphisms  in  the  TNF-α  gene,  located  at
position −863, which may be responsible for transcriptional
regulation of TNF-α protein production [55]. In TNF-α, the
TNF-α (−863)A allele has also been linked with 31% lower
transcriptional  activity  in  reporter  gene  studies  owing  to
reduced binding affinity of the transcription nuclear factor
(NF-κB), especially the form p50-p50 [56,57]. The −863A
allele  has  been  reported  to  be  associated  with  reduced
circulating levels of TNF-α protein [56,58].
Several  publications  have  evaluated  the  association
between the TNF promoter polymorphisms and glaucoma risk
[34-39].  Lin  et  al.  [35]  found  that  the  TNF-α  (−308)G/A
polymorphism has been reported to be associated with POAG
in a Chinese population; Razeghinejad et al. [38] revealed the
importance of the TNF-α (−308)G/A polymorphism in the
development of POAG and PEXG in Iranian patients. The
TNF-α (−308)G/A polymorphism has been reported to be
associated with PEXG in the Pakistani and Turkish population
[36,39]. Funayama et al. [34] investigated sequence variation
in OPTN, the expression of which is induced by TNF-α, and
their association with polymorphisms in the promoter region
of TNF-α at position −308,-857, and −863 in Japanese patients
with POAG. However, no significant difference in genotype
or allelic frequency was noted between patients and Japanese
control  for  the  three  single-nucleotide  polymorphisms  of
TNF-α. Our study showed that the TNF-α (−863)A allele is
associated with POAG protection in a Chinese population.
The genotype and allele frequency in our control population
was  different  from  that  observed  in  Japanese  populations
[34]. The frequency of the TNF-α (−863)A allele were lower
in  Japanese  populations  compared  with  those  in  Chinese
populations (13% versus 29%, respectively; p<0.05). In the
Japanese study, the frequency of the AA genotype was as rare
as 0.5%. In contrast, the frequency of the AA genotype at
−863  was  reported  to  be  more  than  10%  in  Chinese
populations. These findings indicate Chinese and Japanese
have  a  different  genetic  background  at  this  site.  This
phenomenon may be due to ethnic differences, which may
lead to controversial results.
In  our  study,  we  noted  the  TNF-α  (−863)A  allele
polymorphism may be a protective factor in the development
of POAG. Besides the TNF-α gene, previous studies have
noted other cytokine genes (interleukin 1-α, IL-1β) and growth
factor gene (insulin-like growth factor-II) polymorphisms are
associated with an elevated risk of POAG [34,35,59-61]. Lin
et  al.  [35]  found  that  the  IL-1β  (+3953)T  allele  were
significantly  more  common  in  POAG  patients  than  in
controls. In future studies, proteomic analyses may be useful
for  determining  the  exact  roles  of  cytokines  genes  in  the
development of POAG.
Controversy exists regarding whether or not there is an
absolute increased level of TNF protein in the vitreous or
plasma  that  coincides  with  an  increased  level  in  retinal
ganglion tissue among patients with POAG. The genotyping
data obtained in the present study may now enable researchers
to identify potential subpopulations within POAG patients,
TABLE 2. GENOTYPE AND ALLELE FREQUENCIES OF TNF-Α (−863).
TNF-α(-863)
polymorphism POAG (%; n=234) Control (%; n=230) Odds ratio (95% CI) p-value
Genotype
C/C 148 (63%) 120 (52%) 1 NA
C/A 70 (30%) 84 (37%) 0.68 (0.45, 1.01) 0.067
A/A 16 (7%) 26 (11%) 0.5 (0.26, 0.98) 0.037
Allele
C 366 (78%) 324 (70%)    
A 102 (22%) 136 (30%) 0.66 (0.49, 0.89) 0.007
A allele carriage
AA+CA 86 (37%) 110 (48%) 0.63 (0.44, 0.92) 0.017
CC 148 (63%) 120 (52%)    
        Distribution of genotypes and allelic frequencies in primary open angle glaucoma (POAG) and controls. In POAG patients, the
        genotype TNF-α (−863)A/A was less frequent than in controls (7% versus 11%; p=0.037). The frequency of the TNF-α (−863)A
        allele was significantly decreased in POAG group (22% versus 30%, p=0.007).There were significantly lower carriers of the
        TNF-α (−863)A allele among patients with POAG than among controls (37% versus 48%; p=0.017), the odds ratio was 0.63
        (95% CI: 0.44–0.92).
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782who  we  predict  are  likely  to  have  increased  circulating
cytokines  in  the  vitreous  fluid.  These  data  also  further
strengthen the current hypothesis that neuro-inflammation is
a contributing component in the pathogenesis of POAG.
Elevated IOP is an important risk factor for glaucoma.
Thus,  an  understanding  of  the  genes  that  are  involved  in
apoptosis,  oxidative  stress,  mitochondrial  dysfunction  and
regulating  IOP  should  assist  in  the  elucidation  of  the
mechanisms of glaucoma. In our study, glaucoma features
such as IOP and vertical cup-disk ratio were included. There
were  no  significance  between  the  TNF-α  (−863)  allele
frequency and different level of IOP or stage of POAG. The
association still needs further study.
The results of our genetic analysis showed that the TNF-
α (−863) A allele is associated with POAG protection in a
Chinese population. Further studies on POAG patients with
different  ethnicities  are  required  to  further  define  this
association.  The  possibility  that  linkage  disequilibrium
between  TNF-α  gene  polymorphisms  and  other  genes  on
chromosome 6 is the cause of increased risk of POAG can not
be excluded.
In conclusion, our results indicate that the TNF-α (−863)
A  allele  polymorphism  may  be  a  protective  factor  in  the
development of POAG. The data indicate that therapeutic
strategies  designed  to  reduce  TNF-protein  production  or
activity might be a valuable treatment for POAG. Further
insight into the mechanism underlying this relationship may
suggest  new  strategies  for  reducing  the  intensity  of  the
inflammatory  response  and  attenuating  the  progression  of
POAG.
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